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Acceptability of human 
papillomavirus self-
sampling for cervical-
cancer screening in under-
screened Māori and Pasi ka 
women: a pilot study
Naomi Brewer, Sunia Foliaki, Collette Bromhead, Ioana Viliamu-Amusia, 
Litia Pelefoti-Gibson, Tegan Jones, Neil Pearce, John D Potter, 
Jeroen Douwes 
In Aotearoa/New Zealand, there are long-term major ethnic inequalities in cervical-cancer screening, incidence and 
mortality, with Māori and Paciﬁ c women 
having lower screening and higher inci-
dence and mortality rates than European 
New Zealanders.1–5 
Reasons for low participation include 
cost, whakamā (embarrassment/shyness), 
tapu (sacred/taboo), access, models of care 
(eg, a lack of cultural appropriateness), and 
discomfort.5–9 Actions to reduce these barriers 
have been undertaken; however, there has 
been little change in screening coverage.2,10 
Thus, novel strategies for increasing 
screening participation are needed.
Persistent infection of the cervix with any 
of 14 oncogenic human papillomavirus (HPV) 
genotypes can cause cervical cancer and its 
precursor lesions.11 DNA testing for oncogenic 
types of HPV is more sensitive than cytology 
for the detection of high-grade lesions,12 and 
is now recommended by the World Health 
Organization for early detection.13 Therefore, 
primary HPV testing, rather than cytology, is 
being introduced in several countries,14 and 
New Zealand will transition to HPV primary 
screening in 2021.15 
One advantage of HPV-based screening 
is that, unlike cytology-based screening, 
it is possible for women to take a sample 
themselves. Internationally, offering 
ABSTRACT
AIM: To assess whether self-sampling for cervical-cancer screening is acceptable to New Zealand women. 
METHODS: Māori, Pacific and Asian un- or under-screened women aged 30–69 years were asked to: 1) 
examine three self-sampling devices; 2) complete a questionnaire on demographics and experiences 
with the devices; and 3) take a self-sample. Samples were tested ‘o -label’ using the cobas® 4800 human 
papillomavirus (HPV) test (Roche Diagnostics NZ).
RESULTS: Thirty-one Pacific, 12 Māori, nine Asian and four women of other ethnicities participated (mean 
age, 39.5 years). Before trying any devices, 78% indicated a preference to self-sample, compared to 22% 
who preferred a physician-collected sample (PCS). A er trying a device (HerSwab™, 91%; Delphi Screener™, 
14%; cobas  Swab, 13%; 12.5% used >1 device), fewer women (66%) preferred to self-sample next time, 
fewer (16%) preferred a PCS, while 18% expressed no preference. One of 32 samples with valid results (35 
were tested) was positive for HPV ‘other’ oncogenic types.
CONCLUSIONS: This was the first New Zealand study to invite women, including Māori women, to take a 
self-sample for cervical-cancer screening. The pilot study suggests that un- and under-screened women 
generally find self-sampling acceptable and all sample types are suitable for use with the cobas HPV test.
ARTICLE
22 NZMJ 21 June 2019, Vol 132 No 1497ISSN 1175-8716                 © NZMA
www.nzma.org.nz/journal
self-sampling has been shown to increase 
screening uptake,16–21 but no New Zealand 
studies where women have taken a self-
sample have yet been published. The study 
was undertaken to examine the acceptability 
of self-sampling in Māori, Paciﬁ c and Asian 
women, who have known low screening 
rates.4 This pilot study aimed to: 1) examine 
the acceptability of self-sampling among 
un- and under-screened Māori, Paciﬁ c, and 
Asian women; 2) enquire about the level 
of comprehension of the instructions for 
self-sampling devices; 3) develop laboratory 
methods for processing cobas® Chlamydia 
trachomatis/Neisseria gonorrhoeae (CT/NG) 
swabs, Herswab™ and the Delphi Screener™ 
through the cobas 4800 HPV test; and 4) 
contribute ethnic-speciﬁ c data to enhance 
the design of a national randomised 
controlled trial of the acceptability of 
self-sampling.
Methods
In New Zealand, cervical screening is 
recommended in women aged 20–69 years, 
but because the prevalence of HPV infec-
tions in women <30 years is high and most 
infections clear without causing cervical 
abnormalities, the usefulness of HPV testing 
in these women is limited.22,23 Women aged 
30–69 years who had ever been sexually 
active and who had not had a hyster-
ectomy were therefore recruited. Eligible 
women were identiﬁ ed by Porirua Union 
and Community Health Service (PUCHS). 
Initially, recruitment was through mail, but 
this was replaced by recruitment through 
PUCHS nurses’ community outreach and 
home visits, a presentation at a community 
health promotion meeting, and at the regular 
screening clinics. The number of women 
who were invited to participate was not 
recorded but feedback from the clinic staff 
indicated that the number of participants 
was determined by the availability of nurses 
rather than by the willingness of women 
to participate. Any woman who attended a 
screening clinic and was interested in and 
eligible for the study was enrolled when the 
nurses had suﬃ  cient time available.
Participants were asked to: 1) examine 
three different self-sampling devices; 2) 
complete a questionnaire (see Appendix); 
and 3) take a self-sample with at least one 
device (of their choice). The questionnaire 
was completed face-to-face followed by 
self-sampling and cytology at the clinic. 
Participants were given a package that 
included a brochure on cervical cancer 
and HPV infections, and three self-sam-
pling devices, with written and illustrated 
instructions from the device manufacturers. 
The three self-sampling devices were: i) 
HerSwab (Eve Medical), ii) Delphi Screener 
(Rovers Medical Devices), and iii) cobas CT/
NG Swab (Roche Diagnostics NZ). 
The questionnaire was developed for this 
study, based partially on the one used for 
a Delphi Screener study in the US.24 The 
questionnaire inquired about: i) general 
information such as age, occupation and 
ethnicity; and, ii) experience with the 
devices. The women were asked to answer 
questions both before and after using the 
devices to assess whether their actual expe-
riences matched their expectations, and 
whether their experiences changed their 
preferences. The questionnaire also inquired 
about the clarity of the instructions for 
each device. The questionnaire consisted of 
multiple choice and open-ended questions.
The self-samples were stored at room 
temperature for up to 48 hours before labo-
ratory analysis and tested ‘off-label’ using 
the cobas 4800 HPV Test. Samples were 
prepared for testing according to the type of 
collection device. Delphi Screener: the vial 
containing cells in saline was vortexed for 
30 seconds and 1mL of resuspended cells 
were transferred to an 8mL tube (Sarstedt 
GmbH) containing 2mL of PreservCyt® 
Solution, then vortexed again for 30 seconds. 
HerSwab: each brush was snapped into an 
8mL tube containing 2mL of PreservCyt, 
then vortexed for 30 seconds. The cobas 
Swab was vortexed for 30 seconds.25 All 
samples were tested according to the manu-
facturer’s instructions, except as noted for 
the sample preparation.26 The cobas 4800 
HPV test detects all 14 oncogenic HPV types, 
genotyping HPV16 and HPV18 individually 
and pooling the 12 other oncogenic HPV 
types as “other high-risk”.26 HPV results 
were not used for clinical management. All 
women were offered cytology testing, as per 
usual care, which was carried out in accor-
dance with national guidelines and standard 
operating procedures (data not shown).
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Data are reported as prevalences, with 
the open-ended questions reported qualita-
tively. The study was approved by the New 
Zealand Central Health and Disability Ethics 
Committee (14/CEN/211). 
Results
Fifty-six women completed the question-
naire (see Table 1 for demographics), the 
majority of whom only used one self-sam-
pling kit (87.5%; n=49); three used all three 
kits and four used two kits. HerSwab was 
used by 51 participants, Delphi Screener by 
eight, and the cobas Swab by seven. 
Preferences and expectations 
before and a er self-sampling 
Before trying any devices, 78.0% (n=39/50) 
of women said that they would prefer to 
self-sample next time they were due for 
screening, and 22.0% (11/50) said that 
they would prefer a physician-collected 
sample (PCS; six women did not answer 
the question). After trying a device, fewer 
women (65.9%; n=29/44) preferred to self-
sample next time, fewer women (7/44) 
preferred a PCS, and 8/44 expressed no 
preference (12 women did not answer the 
question after trying a device). 
Table 2 shows the participants’ responses 
to general questions before trying any of 
the devices. Only one woman said that 
she would not go for a follow-up test after 
a positive result; she said that this was 
because she would think that she was 
healthy and did not need further testing. 
Table 1: Characteristics of participants.
  Number (%)
Ethnicity
Pacific 31 (55.4)
Māori 12 (21.4)
Asian 9 (16.1)
Other 4 (7.1)
Age# 39.5 (20-61)
Occupation^
Housewife* 18 (32.7)
Healthcare worker$ 13 (23.6)
Education‡ 6 (10.9)
Other 18 (32.7)
Number of kits used by each woman
1 49 (87.5)
2 4 (7.1)
3 3 (5.4)
Kits used
HerSwab 51
Delphi Screener 8
cobas CT/NG Swab 7
#Median (range), date of birth was missing for 
two women; ^Data were missing for one woman. 
Percentages do not equal 100% due to rounding; 
*Includes home-maker, housework and mother; 
$Includes nurse, caregiver and community health 
worker; ‡Includes teacher, home base teacher and 
home educator. CT/NG: Chlamydia trachomatis/
Neisseria gonorrhoeae.
Table 2: Participant responses to questions prior 
to trying self-sampling devices.
  Age <40 
years 
n (%)
Age ≥40 
years
n (%)
Total#
Receive kit 
through post
12 (54.5) 10 (45.5) 22
Collect kit from 
clinic*
13 (44.8) 16 (55.2) 29
Automatically 
sent kit when 
due*$
8 (50.0) 8 (50.0) 16
Written to or 
phoned before 
kit sent*$
16 (48.5) 17 (51.5) 33
Other 0 1 (100.0) 1
Would attend 
follow-up if 
result positive^
19 (45.2) 23 (54.8) 42
Would not 
attend fol-
low-up if result 
positive 
0 1 (100) 1
#Totals exclude women who did not answer the 
question; *plus one woman with missing age; 
$one woman answered that she preferred to be 
automatically sent the kit and that she preferred to 
be telephoned first, so she has been included in both 
categories; ^plus two women with missing age.
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Table 3: Participant responses to questions about the device(s).
Question Response 
HerSwab Delphi Screener cobas CT/NG Swab
Positive* 
n (%)
Negative# 
n (%)
Neutral/
Other
n (%)
No comment/
answer
n
Positive* 
n (%)
Negative# 
n (%)
Neutral/
Other
n (%)
No comment/
answer
n
Positive* 
n (%)
Negative# 
n (%)
Neutral/
Other
n (%)
No comment/
answer
n
Before using
General impression 28 (68.3) 7 (17.1) 6 (14.6) 10 4 (50.0) 4 (50.0) 0 0 4 (100) 0 0 3
Ease of using 43 (89.6) 5 (10.4) N/A 3 5 (71.4) 2 (28.6) N/A 1 7 (100) 0 N/A 0
Ease of following 
instructions
44 (89.8) 5 (10.2) N/A 2 5 (71.4) 2 (28.6) N/A 1 6 (85.7) 1 (14.3) N/A 0
Amount of discom-
fort expected
26 (53.1) 23 (46.9) N/A 2 2 (28.6) 5 (71.4) N/A 1 6 (85.7) 1 (14.3) N/A 0
A er using
Anything unclear in 
instructions^
7 (14.3) 42 (85.7) N/A 2 0 7 (100) N/A 1 1 (14.3) 6 (85.7) N/A 0
Ease of using 36 (92.3) 3 (7.7) N/A 12 6 (85.7) 1 (14.3) N/A 1 6 (100) 0 N/A 1
Were the instructions 
helpful
40 (95.2) 2 (4.8) N/A 9 6 (85.7) 1 (14.3) N/A 1 6 (100) 0 N/A 1
Amount of discom-
fort experienced 
during last cytology 
test
18 (46.2) 21 (53.8) N/A 12 6 (85.7) 1 (14.3) N/A 1 5 (83.3) 1 (16.7) N/A 1
Amount of discom-
fort experienced 
using device
27 (62.8) 16 (37.2) N/A 8 6 (85.7) 1 (14.3) N/A 1 5 (83.3) 1 (16.7) N/A 1
Worry had not done 
test properly^
20 (47.6) 22 (52.4) N/A 9 3 (42.9) 4 (57.1) N/A 1 2 (33.3) 4 (66.7) N/A 1
Using device against 
religious or cultural 
beliefs^
0 43 (100) N/A 8 0 7 (100) N/A 1 2 (33.3) 4 (66.7) N/A 1
Percentages in table are out of the number of women who tried the device and answered the question. Since seven women used more than one kit the total number 
of participants included in the table is 66.
*Positive includes favourable, very easy/easy, none/very little, somewhat agree/agree, and yes; #Negative includes unfavourable, di icult/very di icult, some/a lot, 
somewhat disagree/disagree, and no; ^In this question a negative is a good answer. CT/NG: Chlamydia trachomatis/Neisseria gonorrhoeae.
Participants’ impressions of 
specific devices
Before using any of the devices the 
women’s impressions of the devices were 
mostly positive (Table 3). Before using 
HerSwab, 76.6% (n=36/47) of women said 
that they would prefer to use HerSwab next 
time they need to be screened, compared 
to 23.4% (11/47) who said that they would 
prefer to have a PCS (four women declined 
to answer). After using HerSwab, 63.4% 
(n=26/41) of women stated that they would 
prefer self-sampling, compared to 7/41 
saying that they would prefer to have a PCS 
and 8/41 stating no preference (10 women 
declined to answer). Before using Delphi 
Screener, 4/6 women said that they would 
prefer to self-sample next time, 2/6 said that 
they would prefer to have a PCS, and two 
women declined to answer the question. 
After using Delphi Screener, 6/7 stated that 
they would prefer self-sampling, and 1/7 said 
that they would prefer to have a PCS (one 
woman declined to answer). Finally, before 
using the cobas Swab, all six women said 
that they would prefer to self-sample next 
time (one woman declined to answer). After 
trying the cobas Swab, all of the women who 
answered the question (n=6/7) stated that 
they would prefer self-sampling next time. 
Reasons for preferring to use a self-sampling 
device, a PCS, or for having no preference 
(captured by open questions, after trying a 
device) are given in Table 4.
As shown in Table 3, before using the 
device only 2/5 women who used Delphi 
Screener anticipated experiencing no or 
very little discomfort using the device, but 
after using it 6/8 said that they experienced 
no or very little discomfort.
The majority of the women said that 
there was nothing unclear in the instruc-
tions (Table 3). The only women who used 
HerSwab or the cobas Swab and thought 
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Table 4: Some of the participants’ comments about the devices. 
Comments
HerSwab Delphi Screener cobas CT/NG Swab
Before using
Favourable
“Small, colourful, appears easy”
“Looks like it’s easy to use, small, compact”
“User-friendly”
“Awesome”
“User-friendly” 
“Like a tampon”
“Easy”
“Very easy”
“Awesome” 
Less favourable “Ugh! The way it looks is o -putting”
“Unsure/uncomfortable looking at this, but 
happy to have a go a er this explained”
“Hmmm!!! How does that work and will it 
collect what is needed?”
“Big”
“Large and frightening”
N/A
A er using
For next screening test
Prefer self-
sample 
because…
Comfort and ease; being able to do it 
at home in own time; no appointment 
needed; convenience; no shame; privacy; 
less pain
“Easier”; “more 
comfortable”; 
“confidentially, privacy, 
and convenience”
“Easier”; 
“comfortable”; 
“privacy and 
convenience”; 
“rather do it 
myself”
Prefer cytology 
test because…
Self-sampling was painful; concern about 
not doing self-sampling correctly; cytology 
test would be done properly first time, is 
more thorough and more accurate
No comments given N/A
No preference 
because…
“Will the swab indicate glandular cancers? I 
would like to alternate between self-testing 
and cervical smears”
“Whichever one gives non-contaminated/
reliable result”
N/A N/A
To return sample
Prefer to use at 
home and mail 
to laboratory 
because…
Faster; more convenient; easier and saving 
time
No comments given “Comfortable”
Prefer to use at 
home and take to 
clinic because…
Better hygiene; ease; tamper-proof Sample won’t get lost 
in mail; a lot easier, 
because sample can be 
dropped into clinic on 
way to an errand/work
“Flexibility”; “to 
make sure it gets to 
the clinic”
Prefer to use 
at the clinic 
because…
Ease; safety (including availability of help 
& sample being contamination-free); 
correctness of the procedure
Will not get 
contaminated
N/A
Have no 
preference 
because…
“This was a complete fail. The pink brush 
did not come out at all”
N/A No comments 
given
Comments are either quotes (marked as such) or paraphrased for brevity. CT/NG: Chlamydia trachomatis/Neisseria gonorrhoeae.
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that there was something unclear and who 
wrote a response, said that there were not 
enough instructions. 
Some women said that they would worry 
that they had not done the test correctly: 
47.6% (n=20/42) who used HerSwab, 3/7 who 
used Delphi Screener and 2/6 who used the 
cobas Swab (Table 3).
Preferences for where to self-
sample 
The majority of women who used 
HerSwab (38%, n=16/42) preferred to use it 
at the clinic, but only 1/7 who used Delphi 
Screener, and none who used the cobas 
Swab did so. The majority of women who 
used Delphi Screener (n=5/7) and who used 
the cobas Swab (4/6) said that they would 
prefer to use it at home and take the sample 
to the clinic, as did 29% (12/42) of women 
who used HerSwab. Twenty-four percent 
(n=10/42) of women who used HerSwab said 
that they would prefer to use the device at 
home and mail the sample to the laboratory 
in the future, as did 1/7 who used Delphi 
Screener, and 1/6 who used the cobas Swab. 
Ten percent (n=4/42) of women who used 
HerSwab said that they had no preference, 
while none who used Delphi Screener, and 
1/6 who used the cobas Swab had no pref-
erence. Nine women who used HerSwab 
declined to answer the question, as did one 
who used Delphi Screener, and one who 
used the cobas Swab. Some of the (quali-
tative) reasons given for these preferences 
are given in Table 4.
Would the participants recommend 
using the self-sampling device to a 
friend?
The majority of the women would 
recommend using the device to a friend: 
87.8% (n=36/41) who used HerSwab, 6/7 
Delphi Screener and 6/7 the cobas Swab. 
However, 12.2% (n=5/41, 10 declined to 
answer) of women who used HerSwab, 1/7 
(one declined to answer) Delphi Screener, 
and 1/7 the cobas Swab would not. 
HPV testing
A total of 57 samples were received for 
HPV testing from 56 women. Of these, 22 
samples had been stored for more than 
seven days at room temperature, exceeding 
the acceptable limits for testing, and were 
therefore discarded. The remaining 35 
samples (one woman used two devices) gave 
unremarkable HPV results with one of these 
positive for HPV ‘other’ oncogenic type. 
Three (8.6%) of the samples were invalid/
failed. Both of the samples from the woman 
who provided two (one from HerSwab and 
one from Delphi Screener) were negative.
HerSwab samples frequently returned 
“failed” results from the cobas HPV test, 
which resolved on removal of the sampling 
brush head from the test tube. There were 
additional handling problems with HerSwab 
during the pre-analytical phase, caused by 
sample loss through drying due to no lid 
on the device; cross contamination was 
also a potential issue. The Delphi Screener 
provided a macroscopic bolus of cells and 
the lack of a swab device in vitro meant 
that no issues were encountered when 
processing on the cobas® X480 instrument. 
There were no issues with the cobas Swab.
Discussion
This pilot study, which examined the 
acceptability of self-sampling in un- and 
under-screened Māori, Paciﬁ c and Asian 
women in New Zealand showed that, in 
general, the participants were positive about 
the self-sampling devices, which is in accor-
dance with the hui (of 106 under-screened 
Māori women) ﬁ ndings of Adcock et al.6 The 
participants found the devices easy to use, 
but several were worried that they had not 
taken the sample properly. The majority of 
the participants used only one self-sampling 
kit, and the nurses always presented the 
devices in the same order (HerSwab, Delphi 
Screener, cobas Swab), which explains why 
the HerSwab device was used most often. 
Indeed, the design of the HerSwab presented 
technical diﬃ  culties and contamination 
risks that could affect any HPV testing 
system; future users need to be aware of 
this. To the authors’ knowledge this is the 
ﬁ rst study to show the use of Herswab and 
Delphi Screener with the cobas HPV test, 
albeit with a modiﬁ cation of the US Food 
and Drug Administration approved protocol.
Before trying any devices, 78% of the 
women (n=46/59) said that they would prefer 
to self-sample, rather than have a PCS, next 
time they were due for screening, showing 
that these women largely found the idea of 
self-sampling to be an acceptable alternative 
to a PCS. However, after they had tried using 
a device ‘only’ 70% (n=38/54) preferred that 
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option. Adcock et al6 found that 61% of their 
survey participants (397 under-screened 
Māori women) would prefer to self-sample 
rather than have a PCS. In contrast to the 
current study, a study of 197 low-income, 
recently screened women in New York City, 
US showed an increase in preference for use 
of a self-screen (rather than a PCS).24 The 
difference between the results of the current 
study and those of Jones et al24 may be 
because the participants in the current study 
were un- and under-screened, rather than 
recently screened women. 
The decrease in preference for self-sam-
pling that was found in the current study 
was accompanied by a decrease in the 
preference for a PCS (22%, n=13/59 before 
trying a device, and 15%, n=8/54 afterwards) 
and an ‘increase’ in the number of women 
who expressed no preference after trying 
the device (n=8/54; all eight used HerSwab), 
an option that unfortunately was not 
available in the questionnaire before trying 
the device. Six women did not answer the 
question before trying a device, compared 
with 12 afterwards. So, it is likely that after 
trying a device, women were more inclined 
to state no preference or not answer the 
question rather than that they changed their 
mind about which test they would prefer in 
the future. 
The women in the New York study expe-
rienced less discomfort taking a self-sample 
than they had expected,24 and the majority 
of women in Canadian,27 British28 and 
Australian7 studies found self-sampling 
comfortable. In contrast, of the women who 
only used one device in the current study 
(n=49/56), the majority (70%; 28/40) expe-
rienced the same amount of discomfort as 
they had expected, and nine (23%; 9/40) 
experienced less discomfort than they had 
expected. Nine women did not answer the 
question both before and after trying a 
device. 
The study found that 42% (n=22/52, four 
women did not answer the question) of 
women would prefer to receive the self-sam-
pling kit through the post, but most (58%; 
30/52) would prefer to collect the kit from 
a clinic. Slightly more of the women who 
preferred to receive the kit through the 
post were aged <40 years (55%; n=12/22), 
whereas slightly more of the women who 
preferred to collect the kit from a clinic 
were aged ≥40 years (55%; 16/29). Similarly, 
Adcock et al6 found that 64% of their survey 
participants would be happy to receive a 
kit through the post. The majority (67%; 
n=33/49) of the women said that they would 
prefer advance notice by mail or telephone 
before having a self-sampling kit sent to 
them next time they were due for screening. 
Reasonable postal delays will not affect 
the validity of the HPV self-sample test as 
recent research has shown that dry-brush 
self-samples stored at room temperature for 
up to 32 weeks were stable for both human 
genomic material and HPV.29 Overall, age 
did not seem to have a large inﬂ uence on 
women’s preferences for how to receive 
the kit, but the small numbers meant that 
other possible explanatory factors (such as 
ethnicity) were not able to be examined. 
The ongoing national randomised controlled 
trial of the acceptability of self-sampling is 
further investigating these preferences.
A strength of this pilot study is that it 
included Māori and Paciﬁ c women who 
have persistently low screening coverage 
rates and a high burden of disease.1,3,30 The 
limitations of the study include the small 
sample size, which limits the reliability and 
generalisability of the ﬁ ndings. The number 
of women who were told about the study 
and invited to participate was unfortunately 
not recorded due to the large workload of 
the PUCHS nurses. The participants also 
included women who were younger than 
the target age range, and who were not of 
the target ethnicities. 
Conclusions
This is the ﬁ rst study of HPV self-sam-
pling for cervical-cancer screening in New 
Zealand and the ﬁ rst to include Māori 
women. Although the sample size is small, 
the pilot study suggests that un- and under-
screened New Zealand women generally 
ﬁ nd self-sampling acceptable and, with 
appropriate laboratory validation, all 
sample types will be feasible for use with the 
cobas HPV test.
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Appendix
The following questions were used in the study  questionnaire.
These questions were asked before any devices were used:
1. If you were going to use a self-sampling kit for cervical screening would you prefer to 
receive the kit? 
(Answer options: through the post; collect it from a clinic (such as your family 
doctor); other—please specify.)
2. If you were going to use a self-sampling kit would you prefer to be? 
(Answer options: ‘automatically’ sent the kit when you were due to be screened; 
be written to or phoned ﬁ rst; other—please specify.)
3. Would you go for a follow up test with the doctor (or specialist) if your self-sampling 
result was positive?
These questions were repeated three times in the questionnaire so that women could 
answer them for each device that they tried:
Please answer these questions before you try the [device name]
1. What was your impression of the [device name]?
2. Please indicate how easy or diﬃ  cult you think it will be to use the [device name]?
(Answer options: Very easy; Easy; Diﬃ  cult; Very Diﬃ  cult.)
3. Please indicate how easy or diﬃ  cult you think it will be to follow the user 
instructions?
(Answer options: Very easy; Easy; Diﬃ  cult; Very Diﬃ  cult.)
4. Please indicate the amount of discomfort you think you will experience using the 
[device name]?
(Answer options: Very little; Some discomfort; No discomfort; Very much.)
5. Please indicate which method you would prefer the next time you need to be 
screened? 
(Answer options: Smear test health professional; Use [device name] myself.)
Please answer these questions after you have tried the [device name]
1. Was anything not clear on the instructions for using the [device name]?
(Answer options: Yes; No (If No, please go to Q.x).)
2. What was not clear? 
3. Which method would you choose the next time you need to be tested, self-sampling 
with the [device name] or having a health professional take a specimen during a 
smear test?
(Answer options: Self-sampling; Smear test by a health professional; No 
preference.)
4. Why would you prefer this?
5. If you could use the [device name] which would you prefer?
(Answer options: Use [device name] at home and mailing the specimen to clinic; 
Use [device name] at home and bring the specimen to clinic; Use the [device 
name] at the clinic; No preference.)
6. Why would you prefer this?
7. Please indicate how easy or diﬃ  cult it was to use the [device name]?
(Answer options: Very easy; Easy; Diﬃ  cult; Very Diﬃ  cult.)
8. Please indicate how easy or diﬃ  cult it was to follow the user instructions?
(Answer options: Very easy; Easy; Diﬃ  cult; Very Diﬃ  cult.)
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9. Please indicate the amount of discomfort you experienced during your last smear test 
(please leave blank if you have never had a smear test)?
(Answer options: Very little; Some discomfort; No discomfort; Very much.)
10. Please indicate the amount of discomfort you experienced using the [device name]?
(Answer options: Very little; Some discomfort; No discomfort; Very much.)
11. Please indicate whether you would worry that you had not done the test properly?
(Answer options: Disagree; Somewhat disagree; Somewhat agree; Agree.)
12. Please indicate whether using the [device name] would go against your religious or 
cultural beliefs?
(Answer options: Disagree; Somewhat disagree; Somewhat agree; Agree.)
13. Which method would you prefer the next time you need to be screened?
(Answer options: Smear test by health professional; Use [device name] myself; No 
preference.)
14. Would you recommend using the [device name] to a friend?
(Answer options: Yes; No.)
15. Do you have any last comments on the [device name] or the smear test?
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